Thermo Fisher's Zika diagnosis kit gets emergency FDA authorization
Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share
Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet
The U.S. Food and Drug Administration authorized the emergency use of Thermo Fisher Scientific Inc.'s Zika virus diagnosis kit.
The authorization for the company's TaqPath Zika kit only covers the diagnosis of that particular virus and is not meant to be used for the diagnosis of any other infection.
It has not been FDA-cleared or approved and can only be used by certified laboratories.
